| Authors: |
Uhlik M; OncXerna Therapeutics, Inc., Waltham, MA, United States., Pointing D; Genialis, Inc., Boston, MA, United States., Iyer S; OncXerna Therapeutics, Inc., Waltham, MA, United States., Ausec L; Genialis, Inc., Boston, MA, United States., Štajdohar M; Genialis, Inc., Boston, MA, United States., Cvitkovič R; Genialis, Inc., Boston, MA, United States., Žganec M; Genialis, Inc., Boston, MA, United States., Culm K; OncXerna Therapeutics, Inc., Waltham, MA, United States., Santos VC; OncXerna Therapeutics, Inc., Waltham, MA, United States., Pytowski B; OncXerna Therapeutics, Inc., Waltham, MA, United States., Malafa M; Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States., Liu H; Checkmate Pharmaceuticals, Inc., Cambridge, MA, United States., Krieg AM; Checkmate Pharmaceuticals, Inc., Cambridge, MA, United States., Lee J; Department of Hematology and Oncology, Samsung Medical Center, Seoul, Republic of Korea., Rosengarten R; Genialis, Inc., Boston, MA, United States., Benjamin L; OncXerna Therapeutics, Inc., Waltham, MA, United States. |
